CliffBio
small molecule

SUMATRIPTAN SUCCINATE

SUMATRIPTAN SUCCINATE

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUMATRIPTAN SUCCINATE
Active ingredientSUMATRIPTAN SUCCINATE
StrengthEQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJanuary 2023
Marketing statusDISCN

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.